Alternative delivery of a thermostable inactivated polio vaccine

被引:19
作者
Kraan, Heleen [1 ]
Ploemen, Ivo [1 ]
van de Wijdeven, Gijsbert [2 ]
Que, Ivo [3 ]
Loewik, Clemens [3 ]
Kersten, Gideon [1 ,4 ]
Amorij, Jean-Pierre [1 ]
机构
[1] Intravacc Inst Translat Vaccinol, Bilthoven, Netherlands
[2] Bioneedle Technol Grp BV, Eindhoven, Netherlands
[3] Leiden Univ, Med Ctr, Dept Radiol, Leiden, Netherlands
[4] Leiden Univ, Leiden Acad Ctr Drug Res, Div Drug Delivery Technol, Leiden, Netherlands
关键词
Bioneedles; Vaccine delivery; Biodistribution; Needle free; Adjuvant; D-ANTIGEN; ADJUVANT; IMMUNOGENICITY;
D O I
10.1016/j.vaccine.2015.03.011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In the near future oral polio vaccine (OPV) will be replaced by inactivated polio vaccine (IPV) as part of the eradication program of polio. For that reason, there is a need for substantial amount of safe and more affordable IPV for low-income countries. Bioneedles, which are biodegradable mini-implants, have the potential to deliver vaccines outside the cold-chain and administer them without the use of needles and syringes. In the current study, Bioneedles were filled with IPV, subsequently lyophilized, and antigenic recoveries were determined both directly after IPV-Bioneedle preparation as well as after elevated stability testing. Further, we assessed the immunogenicity of IPV-Bioneedles in rats and the residence time at the site of administration. Trivalent IPV was formulated in Bioneedles with recoveries of 101 10%, 113 18%, and 92 15%, respectively for serotypes 1, 2 and 3. IPV in Bioneedles is more resistant to elevated temperatures than liquid IPV: liquid IPV retained less than half of its antigenicity after 1 day at 45 degrees C and IPV in Bioneedles showed remaining recoveries of 80 10%, 85 4% and 63 4% for the three serotypes. In vivo imaging revealed that IPV administered via Bioneedles as well as subcutaneously injected liquid IPV showed a retention time of 3 days at the site of administration. Finally, an immunogenicity study showed that IPV-filled Bioneedles are able to induce virus-neutralizing antibody titers similar to those obtained by liquid intramuscular injection when administered in a booster regime. The addition of LPS-derivate PagL in IPV-filled Bioneedles did not increase immunogenicity compared to IPV-Bioneedles without adjuvant. The current study demonstrates the pre-clinical proof of concept of IPV-filled Bioneedles as a syringe-free alternative delivery system. Further pre-clinical and clinical studies will be required to assess the feasibility whether IPV-Bioneedles show sufficient safety and efficacy, and may contribute to the efforts to eradicate and prevent polio in the future. (C) 2015 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:2030 / 2037
页数:8
相关论文
共 50 条
[41]   Macromolecular Systems for Vaccine Delivery [J].
Muzikova, G. ;
Laga, R. .
PHYSIOLOGICAL RESEARCH, 2016, 65 :S203-S216
[42]   Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis [J].
Jaiswal, Nishant ;
Singh, Shreya ;
Agarwal, Amit ;
Chauhan, Anil ;
Thumburu, Kiran K. ;
Kaur, Harpreet ;
Singh, Meenu .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (12)
[43]   Antibody responses of Macaca fascicularis against a new inactivated polio vaccine derived from Sabin strains (sIPV) in DTaP-sIPV vaccine [J].
Sato, Y. ;
Shiosaki, K. ;
Goto, Y. ;
Sonoda, K. ;
Kino, Y. .
BIOLOGICALS, 2013, 41 (03) :184-189
[44]   Development of an inactivated candidate vaccine against Chandipura virus (Rhabdoviridae: Vesiculovirus) [J].
Jadi, R. S. ;
Sudeep, A. B. ;
Barde, P. V. ;
Arankalle, V. A. ;
Mishra, A. C. .
VACCINE, 2011, 29 (28) :4613-4617
[45]   Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies [J].
Donadei, Agnese ;
Kraan, Heleen ;
Ophorst, Olga ;
Flynn, Olivia ;
O'Mahony, Conor ;
Soema, Peter C. ;
Moore, Anne C. .
JOURNAL OF CONTROLLED RELEASE, 2019, 311 :96-103
[46]   A phase II, randomized, controlled trial to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine [J].
Tang, Rong ;
Li, Guifan ;
Zhang, Chengfu ;
Zhi, Hengkui ;
Zhu, Jiahong ;
Wang, Jianjun ;
Liang, Qi ;
Hu, Yuemei ;
Li, Changgui .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (11) :2641-2648
[47]   Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine [J].
Ekimov, Aleksei ;
Arunachalam, Arun B. ;
Blake, Taylor ;
Bodle, Jesse ;
Couzens, Laura ;
Dubey, Sitara ;
Eichelberger, Maryna ;
Engelhardt, Othmar G. ;
Gubinelli, Francesco ;
Joshi, Manju ;
Melnyk, Darya ;
Palladino, Giuseppe ;
Rigsby, Peter ;
Rockman, Steven ;
Savina, Natalya ;
Smith, Elena ;
Gilchrist, Shawn A. N. .
VACCINE, 2023, 41 (32) :4639-4647
[48]   Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine [J].
Das, Subash C. ;
Hatta, Masato ;
Wilker, Peter R. ;
Myc, Andrzej ;
Hamouda, Tarek ;
Neumann, Gabrielle ;
Baker, James R., Jr. ;
Kawaoka, Yoshihiro .
VACCINE, 2012, 30 (48) :6871-6877
[49]   Oral inactivated whole cell vaccine for mucosal immunization: ETVAX case study [J].
Walker, Richard I. ;
Bourgeois, A. Louis .
FRONTIERS IN IMMUNOLOGY, 2023, 14
[50]   Inactivated recombinant influenza vaccine: the promising direction for the next generation of influenza vaccine [J].
Shi, Hua ;
Ross, Ted M. .
EXPERT REVIEW OF VACCINES, 2024, 23 (01) :409-418